Kenvue Inc. Common Stock (KVUE)

The enterprise value of the monster deal was estimated at almost $49 billion.

It's been tapped to be a component of a prominent small-cap index.

Dutch Bros is posting impressive revenue growth, while Kimberly-Clark generates massive free cash flow.

A 50-year dividend grower and a monthly income REIT; how J&J and Realty Income build lasting wealth for patient investors.

These three dividend payers are making bold, sometimes expensive moves right now, bets I think will pay off for investors willing to hold for the next 20 years.

Medtronic is following a strategy that has worked well for Johnson & Johnson.

Healthcare giant Johnson & Johnson is looking to become a more profitable and faster-growing business.

One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.

Kenvue's dependable dividend is above average, and it could go even higher if the company is bought by Kimberly-Clark.

Kimberly Clark is a consumer staples Dividend King with a 5% yield, but it is also undergoing a major business transition.

Deal skepticism and litigation fears still weigh on this consumer staples stalwart.

Johnson & Johnson and Merck are healthcare giants with dependable returns that weather economic downturns well.

Kimberly Clark is a lesser-known Dividend King.

Both of these healthcare leaders are Dividend Kings.

Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.

Hsu discusses tariff refunds, China disruptions, and Kenvue integration plans.